Skip to main content

$12.25 -0.23 (-1.84%)

High

$12.50

Low

$12.07

Trades

2,722

Turnover

$3,205,258

Volume

261,029
30 June 2023 at 4:55pm
Register to track NEU and receive email alerts.
Subject
NEU Ann: Change of Director's Interest Notice

NEU Ann: Investor presentation, 15 June 2021

NEU Ann: Initial Director's Interest Notice

NEU Ann: Neuren CEO Jon Pilcher appointed to board of directors

NEU Ann: Neuren to present at MST Access investor conference

NEU Ann: Update - Annual General Meeting 2021

NEU Ann: Positive FDA meetings enable INDs for three Phase 2 trials

NEU Ann: Virtual AGM online guide

NEU Ann: Notice of Annual General Meeting/Proxy Form

NEU Ann: New patent issued to 2032 for Neuren's trofinetide in Canada

NEU Ann: Appendix 4G

NEU Ann: Annual Report to shareholders

NEU Ann: Quarterly report and cash flow statement for Q1 2021

NEU Ann: Investor presentation, 23 March 2021

NEU Ann: S&P DJI Announces March 2021 Quarterly Rebalance

NEU Ann: Neuren successfully completes manufacturing for Phase 2

NEU Ann: Neuren corporate presentation, 24 February 2021

NEU Ann: Neuren approaching transforming milestones in 2021

NEU Ann: Preliminary Final Report and 2020 full year accounts

NEU Ann: Change of Director's Interest Notice

NEU Ann: Notification of investor briefing webinar

NEU Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline

NEU Ann: Successful Phase 1 trial for Neuren's NNZ-2591

NEU Ann: Quarterly report and cash flow statement for Q4 2020

NEU Ann: European Commission grants 3 NNZ-2591 Orphan designations

NEU Ann: Notification of investor briefing webinar

NEU Ann: Positive opinion for all 3 Orphan applications in Europe

NEU Ann: Approval received for final stage of NNZ-2591 clinical trial

NEU Ann: Quarterly report and cash flow statement for Q3 2020

Register to track NEU and receive email alerts.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
PBP
RCE
SPL